

Actelion Awards Grants to 2021 ENTELLIGENCE™ Young Investigators for Research in Pulmonary Vascular Disease, Virtual Award Ceremony – September 13, 2021:

Actelion Pharmaceuticals US, Inc., and the ENTELLIGENCE Steering Committee recognized four young researchers and their mentors for their efforts in advancing research in pulmonary vascular disease this year. Each researcher will receive a 12-month mentored grant of up to \$100,000, funded through the Janssen/Actelion-supported ENTELLIGENCE program. The announcement was made today during the annual virtual awards ceremony. The recipients of the 2021 awards gave an overview of their proposed work during the ceremony.

“Now in our 17th year of the ENTELLIGENCE Young Investigator Program, the ENTELLIGENCE Steering Committee members are once again proud to award four new innovative grants to promising young investigators in the field of pulmonary vascular disease. Each year, very high-quality research proposals come before us to evaluate their merits. As in past years, the decisions for funding were extremely competitive, making the selection of four awardees challenging,” said Ronald J. Oudiz, MD, ENTELLIGENCE Steering Committee Chairman and Director of the Liu Center for Pulmonary Hypertension at the Lundquist Institute for Biomedical Innovation and Research at Harbor-UCLA Medical Center.

During the awards ceremony, Janssen Global Head for the Pulmonary Hypertension Therapeutic Area, Neil Davie, PhD, delivered a message about Janssen’s commitment to Pulmonary Hypertension research. “This year’s winners have made significant strides in pulmonary hypertension research and are at the forefront of advancing care for people with PAH [pulmonary arterial hypertension]. We congratulate the awardees and look forward to their ongoing contributions to the future of pulmonary hypertension research.”

Many prior ENTELLIGENCE awardees and mentors were in attendance at the awards ceremony and were proudly recognized. “The ENTELLIGENCE Steering Committee is thrilled with the success of this longstanding program. So much exciting research has come before us over the years; we couldn’t be more pleased,” said Dr. Oudiz. “For the past 16 award cycles, ENTELLIGENCE, with more than \$6.6 million in funding, has supported innovative basic, translational, and clinical research that has fostered the development of 75 young investigators’ careers in pulmonary vascular disease. During this time, the awardees’ research findings have been published in more than 75 peer-reviewed journals. With the momentum of their ENTELLIGENCE awards, many young investigators have obtained extramural funding to continue their research in pulmonary vascular disease,” Oudiz said.

CONGRATULATIONS TO THE 2021 WINNERS

 <p>MEGNAN M. CIBULIS, MD MSO Mentors: Samuel Brown, MD; Corey Ventetuolo, MD Co-Investigators: Mark Dodson, MD; Tim Lahm, MD Intermountain Medical Center Murray, Utah Title: Biological Sex and Sex-hormones Moderate Right Ventricular (RV) Dysfunction and Recovery in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)</p>	 <p>BENJAMIN STEINBERG, MD Mentors: Marc De Perrot, MD; Wolfgang Kuebler, MD Co-Investigator: Neil Goldenberg, MD The Hospital for Sick Children Program in Neuroscience and Mental Health Toronto, Ontario, CANADA Title: Therapeutic Targeting of Gasdermin D in Pulmonary Arterial Hypertension</p>	 <p>JULIE DILLARD, MD Mentors: Bernadette Chen, MD; Noah Hillman, MD St. Louis University St. Louis, Missouri Title: The Role of PDE3 Isoforms in a Murine Model of Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension</p>	 <p>RUBEN MYLVAGANAM, MD Mentors: Michael Cuttica, MD; Ravi Kalhan, MD Northwestern Memorial Hospital Chicago, Illinois Title: Exploring the Role of T-Cell Associated Pulmonary Vascular Injury and Right Ventricular Dysfunction</p>
---	--	--	---

About ENTELLIGENCE

The ENTELLIGENCE program was established by Actelion in 2005 to support basic science, translational, and clinical research related to pulmonary vascular disease. The program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research in pulmonary hypertension (PH) related to expanding our knowledge of the pathways involved in pulmonary vascular disease. ENTELLIGENCE is led by a steering committee composed of leaders in the field of PH.

For more information regarding the Young Investigator Program and the upcoming grant cycle, please visit www.ENTELLIGENCEMD.org. Please contact the program administrators at Medtelligence (info@medtelligence.net) with any questions.



The ENTELLIGENCE™ Young Investigator program is supported through an educational grant from Actelion Pharmaceuticals US, Inc.